EnVVeno Medical Corporation (NASDAQ:NVNO) | WebDisclosure

Switch to English

8306	Sociétés
115295	Mots-clés
55580	Articles
62603	Communiqués

Accueil
Sociétés
EnVVeno Medical Corporation

BRÈVE

publiée le 24/04/2024 à 12:20, il y a 6 mois 28 jours

Significant Clinical Improvements Reported in enVVeno Medical's VenoValve Pivotal Trial

FDA Approval Clinical Trial VenoValve Charing Cross Symposium Venous Disease
COMMUNIQUÉ DE PRESSE

publié le 24/04/2024 à 12:15, il y a 6 mois 28 jours

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
enVVeno Medical presents positive efficacy data on VenoValve from SAVVE U.S. pivotal trial at Charing Cross International Symposium, showing clinical improvement for severe CVI patients

FDA Approval VenoValve SAVVE Trial CVI Patients Venous Disease
BRÈVE

publiée le 16/04/2024 à 15:05, il y a 7 mois 6 jours

EnVVeno Medical présentera de nouvelles données sur l'efficacité de VenoValve au symposium de Charing Cross

Essais Cliniques EnVVeno Medical Insuffisance Veineuse Chronique VenoValve Symposium De Charing Cross
BRÈVE

publiée le 16/04/2024 à 15:05, il y a 7 mois 6 jours

EnVVeno Medical to Present New VenoValve Efficacy Data at Charing Cross Symposium

Clinical Trials EnVVeno Medical VenoValve Chronic Venous Insufficiency Charing Cross Symposium
COMMUNIQUÉ DE PRESSE

publié le 16/04/2024 à 15:00, il y a 7 mois 6 jours

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
enVVeno Medical Corporation to present additional topline efficacy data from VenoValve U.S. pivotal trial at 2024 Charing Cross International Symposium in London. Data to review clinical status of severe Chronic Venous Insufficiency patients post VenoValve implantation

VenoValve Chronic Venous Insufficiency EnVVeno Medical Corporation SAVVE Trial Charing Cross International Symposium
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 7 mois 13 jours

EnVVeno Medical nomme Andrew Cormack au poste de directeur commercial pour diriger la commercialisation de VenoValve®

EnVVeno Medical VenoValve® Insuffisance Veineuse Chronique (IVC) Étude Pivot Américaine SAVVE Stratégie De Commercialisation
BRÈVE

publiée le 09/04/2024 à 14:50, il y a 7 mois 13 jours

EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

EnVVeno Medical VenoValve® Chronic Venous Insufficiency (CVI) SAVVE U.S. Pivotal Study Commercialization Strategy
COMMUNIQUÉ DE PRESSE

publié le 09/04/2024 à 14:45, il y a 7 mois 13 jours

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
enVVeno Medical Corporation appoints Andrew Cormack as Chief Commercial Officer to drive VenoValve's commercialization strategy. PMA application for FDA approval on track for Q4 2024

FDA Approval VenoValve EnVVeno Medical Corporation Commercialization Strategy Andrew Cormack
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 8 mois 7 jours

EnVVeno Medical to Showcase Its Innovations in an Upcoming Virtual Investor Event

EnVVeno Medical Medical Innovation Virtual Investor Event Venous Disease Treatment Corporate Overview
BRÈVE

publiée le 15/03/2024 à 14:05, il y a 8 mois 7 jours

EnVVeno Medical présentera ses innovations lors d'un prochain événement virtuel pour les investisseurs

Innovation Médicale EnVVeno Medical Événement Virtuel Pour Les Investisseurs Traitement Des Maladies Veineuses Vue D'ensemble De L'entreprise

Les Echos

Publié le 22/11/2024 à 14:35, il y a 35 minutes

Communiqué de presse Thales
Publié le 22/11/2024 à 14:35, il y a 35 minutes

Thales Press release
Publié le 21/11/2024 à 06:58, il y a 1 jour 8 heures

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 8 heures

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 8 heures

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 22/11/2024 à 14:45, il y a 25 minutes

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Publié le 22/11/2024 à 14:30, il y a 40 minutes

Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best
Publié le 22/11/2024 à 14:20, il y a 50 minutes

Plaintree Systems Inc. Announces Second Quarter Fiscal 2025 Results
Publié le 22/11/2024 à 14:05, il y a 1 heure 5 minutes

First Gas-To-Power Data Centre Connection
Publié le 22/11/2024 à 14:00, il y a 1 heure 10 minutes

Clear Start Tax Warns Taxpayers About Upcoming IRS Collection Changes in 2025

Voir tout ACCESSWIRE

EQS Group

Publié le 22/11/2024 à 14:46, il y a 23 minutes

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Publié le 22/11/2024 à 14:45, il y a 24 minutes

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Publié le 22/11/2024 à 14:44, il y a 26 minutes

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Publié le 22/11/2024 à 14:43, il y a 27 minutes

Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc
Publié le 22/11/2024 à 14:42, il y a 28 minutes

Form 8.3 - The Vanguard Group, Inc.: Hargreaves Lansdown plc